Large-scale testing (Phase 3)Study completedNCT00443053
What this trial is testing
Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis)
Who this might be right for
Thrombosis, Venous
GlaxoSmithKline 3,002